Biobeat Ltd. is a medical technology company specializing in the development and manufacturing of advanced AI-driven wearable devices for remote patient monitoring. Their solutions provide continuous, non-invasive, and medical-grade measurements of vital signs such as cuffless blood pressure, pulse rate, respiratory rate, blood oxygen saturation, temperature, and more. Biobeat's platform aims to improve patient outcomes, reduce healthcare costs, and enhance clinical decision-making by providing real-time patient data and actionable insights. Their technology is utilized in various settings including hospitals, clinics, home care, and clinical research. Biobeat's products are FDA-cleared and CE-marked.
The headquarters serves as the primary hub for research and development, corporate leadership, strategic planning, and global operations management.
The facility likely houses advanced R&D labs for medical device development, sensor technology innovation, and AI algorithm refinement, characteristic of a cutting-edge MedTech company.
The work culture at Biobeat's HQ is expected to be innovative, fast-paced, and collaborative, focusing on scientific excellence and a mission-driven approach to improving healthcare.
Being located in Israel's 'Silicon Wadi' provides Biobeat access to a rich ecosystem of tech talent, research institutions, and investment opportunities, crucial for its growth and innovation in the competitive MedTech landscape.
Biobeat supports healthcare providers and patients globally with its remote patient monitoring solutions. Key functions supported globally include sales and distribution networks, clinical trial support across multiple regions, technical support for its wearable devices and cloud platform, and business development activities to forge international partnerships. Their FDA clearance and CE mark facilitate presence in North America and Europe, respectively, among other regions.
23 HaTa'asiya Street
Petah Tikva
Central District
Israel
Address: No specific public street address for a physical branch office, likely operates through regional representatives or a U.S. entity for business development and FDA regulatory affairs.
To expand Biobeat's footprint in the North American market, leveraging its FDA clearances for its remote patient monitoring solutions across various healthcare settings.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Biobeat' leadership includes:
Biobeat has been backed by several prominent investors over the years, including:
Biobeat Ltd. has maintained a relatively stable core executive team. While specific hires or exits within the last 12 months are not prominently publicized, the company continues to strengthen its leadership. For instance, Danny Lange's appointment as CPO in early 2023 was a significant addition, slightly predating the 12-month window but indicative of strategic team building. No major departures have been recently announced.
Discover the tools Biobeat uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Biobeat Ltd. likely uses common professional email formats. Based on industry standards and observed patterns for technology companies of its size, the most probable format is [first name]@[companydomain.com] or [first initial][last name]@[companydomain.com].
[first]@biobeat.com or [firstinitial][lastname]@biobeat.com
Format
arik@biobeat.com or abenishay@biobeat.com
Example
70%
Success rate
PR Newswire • February 27, 2024
Biobeat announced it has received FDA 510(k) clearance for its wearable continuous cuffless blood pressure monitoring device specifically designed for infants and newborns. This marks a significant advancement in neonatal care, providing a non-invasive method for continuous vital sign monitoring in the most vulnerable patients....more
Biobeat Press Release / PR Newswire • January 9, 2023
Biobeat announced the appointment of Danny Lange, a renowned expert in Artificial Intelligence and Machine Learning, as its new Chief Product Officer. Lange previously led AI/ML initiatives at major tech companies like Amazon, Microsoft, Uber, and Unity Technologies....more
GlobeNewswire • September 7, 2022
Biobeat secured $20 million in funding led by Reliance Industries Limited's associate company. The investment aims to accelerate Biobeat's global expansion and further develop its AI-powered remote patient monitoring technology....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Biobeat, are just a search away.